

Date: 7th August, 2020

To,
The Manager,
The BSE Limited
1st Floor, Phiroze Jeejeebhoy Towers,
Dalal Street, Fort,
Mumbai - 400 001

Dear Sir,

Sub: Outcome of Board Meeting

With reference to the captioned subject, the exchange is hereby informed that the Board of Directors of Alembic Limited at its meeting held today has inter alia approved the Unaudited Financial Results of the Company for the quarter ended on 30th June, 2020.

We enclose herewith the following:

- 1) Consolidated Unaudited Financial Results of the Company for the quarter ended on 30th June, 2020.
- 2) Standalone Unaudited Financial Results of the Company for the quarter ended on 30th June, 2020.
- 3) Limited Review Report by Statutory Auditors on Consolidated as well as on Standalone Unaudited Financial Results.

The time of commencement of the Board Meeting was 11:15 a.m. and the time of conclusion was 11:55 a.m.

We request you to kindly take the same on your record.

Thanking you.

Yours faithfully,
For Alembic Limited


Drigesh Mittal
Company Secretary



Encl.: A/a

ALEMBIC LIMITED

Statement of Consolidated Unaudited Financial Results for the Quarter ended 30th June, 2020

Rs. in Lakhs

Sr. No.	Particulars	Quarter Ended			Year Ended
		30.06.2020 (Unaudited)	31.03.2020 (Audited)	30.06.2019 (Unaudited)	31.03.2020 (Audited)
1	Revenue from Operations	1,339	1,148	2,603	7,393
2	Other Income	282	5,727	148	9,340
3	Total Income	1,621	6,876	2,752	16,733
4	Expenses				
	Cost of Materials Consumed	253	240	585	2,459
	Cost of Construction	0	1	0	28
	Changes in Inventories of Finished Goods and WIP	72	(94)	873	684
	Employee Benefit Expenses	620	550	545	2,079
	Finance Costs	9	9	7	29
	Depreciation and amortisation expense	93	90	69	323
	Other Expenses	320	517	459	1,815
	Total Expenses	1,367	1,313	2,538	7,416
5	Profit Before Tax	254	5,563	213	9,317
6	Tax Expenses				
	Current Tax	12	-	49	-
	Deferred Tax	31	16	15	28
	Short / (Excess) Provision of earlier years	-	-	-	(15)
7	Net Profit after tax for the Period	211	5,547	149	9,303
8	Share of Associate's Profit	8,641	5,996	3,529	23,608
9	Net Profit after tax and Share of Associate's Profit	8,852	11,543	3,678	32,912
10	Other Comprehensive Income				
	A (i) Items that will not be reclassified to Profit or Loss	3,558	(4,553)	2,269	(2,230)
	(ii) Income tax relating to items that will not be reclassified to Profit or Loss	(390)	547	(252)	284
	B (i) Items that will be reclassified to Profit or Loss	(8)	103	42	225
	(ii) Income tax relating to items that will be reclassified to Profit or Loss	-	-	-	-
11	Total Comprehensive Income/(Loss) for the Period	12,011	7,640	5,737	31,190
12	Paid up Equity Share Capital (Face Value of Rs 2/- per share)	5,135.64	5,135.64	5,135.64	5,135.64
13	Other Equity (excluding Revaluation Reserve)				1,26,948
14	Earnings per equity share (FV Rs. 2/- per share) Basic & Diluted (In Rs.)	3.45	4.50	1.43	12.82



Alembic Limited
Segment wise Consolidated Revenue and Results

Rs. In Lakhs

Sr. No.	Particulars	Quarter Ended			Year Ended
		30.06.2020 (Unaudited)	31.03.2020 (Audited)	30.06.2019 (Unaudited)	31.03.2020 (Audited)
1	Segment Revenue				
	Revenue from Operations				
	a. Active Pharmaceutical Ingredients Business	727	580	2,040	5,109
	b. Real Estate Business	612	568	563	2,284
	Total Income from Operations (Net)	1,339	1,148	2,603	7,393
2	Segment Results (Profit (+)/ Loss (-) before Taxes and interest from each segment)				
	a. Active Pharmaceutical Ingredients Business	(52)	(101)	169	155
	b. Real Estate Business	100	22	39	218
	Total	48	(79)	209	373
	Unallocable Income and Expenditure				
	(i) Interest Expense	(9)	(9)	(7)	(29)
	(ii) Dividend Income and Gain/(Loss) on Fair Value Change of Financial Asset	151	5,608	52	8,847
	(iii) Other Income / (Expense)	63	44	(41)	125
	Total Profit Before Tax	254	5,563	213	9,317
3	Segment Assets				
	a. Active Pharmaceutical Ingredients Business	15,012	20,414	17,134	20,414
	b. Real Estate Business	13,798	13,399	10,356	13,399
	c. Unallocated	1,30,787	1,13,259	1,04,854	1,13,259
	Total	1,59,597	1,47,072	1,32,345	1,47,072
4	Segment Liabilities				
	a. Active Pharmaceutical Ingredients Business	1,653	1,577	2,370	1,577
	b. Real Estate Business	3,504	3,522	2,673	3,522
	c. Unallocated	624	169	711	169
	Total	5,781	5,268	5,755	5,268

Notes:

- The above results have been reviewed by Statutory Auditors, recommended by Audit Committee and approved by the Board of Directors of the Company.
- Due to the on-going pandemic, the quarter ended 30th June, 2020 was adversely impacted. Due to unavailability of adequate labour, Real estate construction activity has slowed down significantly. The rental business also faces short term challenges. The API segment, although being a part of essential services is marginally impacted.

The Company's management has made an internal assessment and believes that the impact is likely to be short term in nature and does not foresee any medium to long term risk in company's ability to continue as a going concern.

- The previous quarter's / year's figures have been regrouped / rearranged wherever necessary to make it comparable with the current quarter / year.

For Alembic Limited



Place : Vadodara
Date : 07th August, 2020

Chirayu Amin
Chairman

Independent Auditor's Review Report on Unaudited Consolidated Quarterly Financial Results of the Company Pursuant to the Regulation 33 of the SEBI (Listing Obligations and Disclosure Requirements) Regulations, 2015 (as amended)**To the Board of Directors of Alembic Limited**

1. We have reviewed the accompanying Statement of unaudited consolidated financial results of **Alembic Limited** ("the Parent") and its subsidiary (the Parent and its subsidiary together referred to as "the Group") for the quarter ended 30th June, 2020 ("the Statement") attached herewith, being submitted by the Parent pursuant to the requirement of Regulation 33 of the SEBI (Listing Obligations and Disclosure Requirement) Regulations, 2015, as amended (the "Listing Regulations").
2. This Statement, which is the responsibility of the Parent's Management and approved by the Parent's Board of Directors, has been prepared in accordance with the recognition and measurement principles laid down in the Indian Accounting Standard 34, ("Ind AS 34") "Interim Financial Reporting" prescribed under Section 133 of the Companies Act, 2013 as amended, read with relevant rules issued thereunder and other accounting principles generally accepted in India. Our responsibility is to express a conclusion on the Statements based on our review.
3. We conducted our review of the Statement in accordance with the Standard on Review Engagements (SRE) 2410, "Review of Interim Financial Information Performed by the Independent Auditor of the Entity" issued by the Institute of Chartered Accountants of India. This standard requires that we plan and perform the review to obtain moderate assurance as to whether the financial statement is free of material misstatement. A review of interim financial information consists of making inquiries, primarily of persons responsible for financial and accounting matters, and applying analytical and other review procedures. A review is substantially less in scope than an audit conducted in accordance with Standards on Auditing and consequently does not enable us to obtain assurance that we would become aware of all significant matters that might be identified in an audit. Accordingly, we do not express an audit opinion.

We also performed procedures in accordance with the circular issued by the Securities Exchange Board of India under Regulation 33 (8) of the Securities and Exchange Board of India (Listing Obligations and Disclosure Requirements) Regulations, 2015, to the extent applicable

4. The statement includes results of the following entities:
 - i. Alembic City Limited (Subsidiary)
 - ii. Alembic Pharmaceuticals Limited (Associate)
5. Based on our review conducted and procedures performed as stated in paragraph 3 above and based on the consideration referred to in paragraph 6 below, nothing has come to our attention that causes us to believe that the accompanying Statement, prepared in accordance with recognition and measurement principles laid down in the aforesaid Indian Accounting Standards ('Ind AS') specified under Section 133 of the Companies Act, 2013 as amended, read with relevant rules issued thereunder and other accounting principles generally accepted in India, has not disclosed the information required to be disclosed in terms of the Listing Regulations, including the manner in which it is to be disclosed, or that it contains any material misstatement.



6. We did not review the financial result of a subsidiary included in the unaudited consolidated financial results, whose financial results reflect total revenue of Rs. 108.98 lakhs, total net loss after tax of Rs. 20.83 Lakhs and total comprehensive loss of Rs. 20.39 Lakhs for the quarter ended 30th June, 2020. The unaudited consolidated financial results also include the Group's share of net profit after tax of Rs. 8,641.21 Lakhs and total comprehensive income of Rs. 8,472.66 lakhs quarter ended 30th June, 2020, as considered in the statement, in respect of an associate. These financial results have been reviewed by other auditors whose reports have been furnished to us by the Management and our conclusion on the Statement, in so far as it relates to the amounts and disclosures included in respect of a subsidiary and associate, is based solely on the reports of the other auditors and the procedures performed by us as stated in paragraph 3 above. Our conclusion on the unaudited consolidated quarterly financial results is not modified with respect of the above matter.

For **CNK & Associates LLP**

Chartered Accountants

Firm Registration No. 101961W/W-100036

Alok Shah

Alok Shah

Partner

Membership No. 042005

Place : Vadodara

Date : 07th August, 2020

UDIN : 20042005AAAAKF7968



Statement of Standalone Unaudited Financial Results for the Quarter ended 30th June, 2020

Rs. in Lakhs

Sr. No.	Particulars	Quarter Ended			Year Ended
		30.06.2020 (Unaudited)	31.03.2020 (Audited)	30.06.2019 (Unaudited)	31.03.2020 (Audited)
1	Revenue from Operations	1,310	1,136	2,603	7,369
2	Other Income	281	5,729	150	9,347
3	Total Income	1,591	6,865	2,753	16,716
4	Expenses				
	Cost of Materials Consumed	253	240	585	2,459
	Cost of Construction	0	1	0	28
	Changes in Inventories of Finished Goods and WIP	72	(94)	873	684
	Employee Benefit Expenses	620	550	545	2,079
	Finance Costs	6	8	7	28
	Depreciation and amortisation expense	93	90	69	323
	Other Expenses	296	508	409	1,748
	Total Expenses	1,341	1,303	2,488	7,348
5	Profit Before Tax	250	5,562	265	9,368
6	Tax Expenses				
	Current Tax	12	-	49	-
	Deferred Tax	31	16	15	28
	Short / (Excess) Provision of earlier years	-	-	-	(15)
7	Net Profit after tax for the Period	207	5,546	201	9,355
8	Other Comprehensive Income				
	(i) Items that will not be reclassified to Profit or Loss	3,751	(4,336)	2,409	(1,894)
	(ii) Income tax relating to items that will not be reclassified to Profit or Loss	(424)	510	(282)	226
9	Total Comprehensive Income/(Loss) for the Period	3,534	1,719	2,328	7,687
10	Paid up Equity Share Capital (Face Value of Rs 2/- per share)	5,135.64	5,135.64	5,135.64	5,135.64
11	Other Equity (excluding Revaluation Reserve)				33,454
12	Earnings per equity share (FV Rs. 2/- per share) Basic & Diluted (In Rs.)	0.08	2.16	0.08	3.64



Alembic Limited
Segment wise Standalone Revenue and Results

Rs. In Lakhs

Sr. No.	Particulars	Quarter Ended			Year Ended
		30.06.2020 (Unaudited)	31.03.2020 (Audited)	30.06.2019 (Unaudited)	31.03.2020 (Audited)
1	Segment Revenue				
	Revenue from Operations				
	a. Active Pharmaceutical Ingredients Business	727	580	2,040	5,109
	b. Real Estate Business	582	556	563	2,260
	Total Income from Operations (Net)	1,310	1,136	2,603	7,369
2	Segment Results (Profit (+)/ Loss (-) before Taxes and interest from each segment)				
	a. Active Pharmaceutical Ingredients Business	(52)	(101)	169	155
	b. Real Estate Business	93	20	39	269
	Total	42	(81)	209	424
	Unallocable Income and Expenditure				
	(i) Interest Expense	(6)	(8)	(7)	(28)
	(ii) Dividend Income and Gain/(Loss) on Fair Value Change of Financial Asset	151	5,607	52	8,847
	(iii) Other Income / (Expense)	63	44	11	125
	Total Profit Before Tax	250	5,562	265	9,368
3	Segment Assets				
	a. Active Pharmaceutical Ingredients Business	15,012	20,414	17,134	20,414
	b. Real Estate Business	13,707	13,288	10,356	13,288
	c. Unallocated	28,775	19,725	21,834	19,725
	Total	57,494	53,428	49,325	53,428
4	Segment Liabilities				
	a. Active Pharmaceutical Ingredients Business	1,653	1,577	2,370	1,577
	b. Real Estate Business	3,372	3,372	2,673	3,372
	c. Unallocated	624	169	711	169
	Total	5,649	5,118	5,755	5,118

Notes:

- The above results have been reviewed by Statutory Auditors, recommended by Audit Committee and approved by the Board of Directors of the Company.
- Due to the on-going pandemic, the quarter ended 30th June, 2020 was adversely impacted. Due to unavailability of adequate labour, Real estate construction activity has slowed down significantly. The rental business also faces short term challenges. The API segment, although being a part of essential services is marginally impacted.

The Company's management has made an internal assessment and believes that the impact is likely to be short term in nature and does not foresee any medium to long term risk in company's ability to continue as a going concern.
- The previous quarter's / year's figures have been regrouped / rearranged wherever necessary to make it comparable with the current quarter / year.

For Alembic Limited

Place : Vadodara
Date : 07th August, 2020



Chirayu Amin
Chairman

Independent Auditor's Review Report on Unaudited Standalone Quarterly Financial Results of the Company Pursuant to the Regulation 33 of the SEBI (Listing Obligations and Disclosure Requirements) Regulations, 2015 (as amended)**To the Board of Directors of Alembic Limited**

1. We have reviewed the accompanying Statement of Unaudited Standalone Financial results of **Alembic Limited** ("the Company") for the quarter ended 30th June, 2020 ("the Statement") attached herewith, being submitted by the Company pursuant to the requirement of Regulation 33 of the SEBI (Listing Obligations and Disclosure Requirement) Regulations, 2015, as amended (the "Listing Regulations").
2. This Statement, which is the responsibility of the Company's Management and approved by the Board of Directors, has been prepared in accordance with the recognition and measurement principles laid down in the Indian Accounting Standard 34, ("Ind AS 34") "Interim Financial Reporting" prescribed under Section 133 of the Companies Act, 2013 as amended, read with relevant rules issued thereunder and other accounting principles generally accepted in India. Our responsibility is to express a conclusion on the Statements based on our review.
3. We conducted our review of the Statement in accordance with the Standard on Review Engagements (SRE) 2410, "Review of Interim Financial Information Performed by the Independent Auditor of the Entity" issued by the Institute of Chartered Accountants of India. This standard requires that we plan and perform the review to obtain moderate assurance as to whether the financial statement is free of material misstatement. A review of interim financial information consists of making inquiries, primarily of persons responsible for financial and accounting matters, and applying analytical and other review procedures. A review is substantially less in scope than an audit conducted in accordance with Standards on Auditing and consequently does not enable us to obtain assurance that we would become aware of all significant matters that might be identified in an audit. Accordingly, we do not express an audit opinion.
4. Based on our review conducted as above, nothing has come to our attention that causes us to believe that the accompanying Statement of Unaudited standalone financial results prepared in accordance with recognition and measurement principles laid down in the aforesaid Indian Accounting Standards ('Ind AS') specified under Section 133 of the Companies Act, 2013 as amended, read with relevant rules issued thereunder and other accounting principles generally accepted in India, has not disclosed the information required to be disclosed in terms of the Listing Regulations, including the manner in which, it is to be disclosed, or that it contains any material misstatement.

For **CNK & Associates LLP**

Chartered Accountants

Firm Registration No. 101961W/W-100036

**Alok Shah**

Partner

Membership No. 042005

Place : Vadodara

Date : 07th August, 2020

UDIN : 20042005AAAAKE8188

